Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-4139 Tablets Receive Drug Clinical Trial Approval Notice

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-4139 Tablets, and will soon initiate clinical trials. HRS-4139 Tablets are a Class 1 innovative drug independently developed by the company. In animal models, it can effectively improve psoriasis symptoms and inhibit inflammatory responses. According to searches, no drugs targeting the same target have been approved for marketing domestically or internationally. As of now, the cumulative R&D investment in HRS-4139 Tablets and related projects is approximately RMB 20.4 million (unaudited).